Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eladynos

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

- PMLiVE

Repatha outcomes data “less than stellar”

Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements

Actelion HQ Switzerland

EU nod for Actelion’s skin cancer drug Ledaga

Still need to meet CHMP post-approval requirements

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Hopes ENDEAVOR trial results will give it an edge over Takeda's brand

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

AZ nears EU approval for hyperkalaemia drug Lokelma

CHMP adopts positive opinion for the potassium-binding treatment

- PMLiVE

AZ moves closer to Lynparza filing in breast cancer

PARP inhibitor showed “statistically-significant and clinically-meaningful” improvement in phase III trial

Sanofi reception

Praluent can stay on market for now, says US court

Sanofi and Regeneron win appeal to suspended permanent injunction sought by Amgen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links